ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 07/25/2025 at 08:00, 10 months 28 days ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds
BRIEF

published on 07/24/2025 at 14:45, 10 months 29 days ago

Abivax's $650M Public Offering of ADS

Biotechnology Abivax Capital Increase Public Offering Ads
BRIEF

published on 07/24/2025 at 14:45, 10 months 29 days ago

Abivax lance une offre publique d'ADS de 650 millions de dollars

Biotechnologie Abivax Augmentation De Capital Offre Publique PUBLICITÉS
PRESS RELEASE

published on 07/24/2025 at 14:40, 10 months 29 days ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements thérapeutiques pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Traitements Thérapeutiques Maladies Inflammatoires
PRESS RELEASE

published on 07/24/2025 at 14:40, 10 months 29 days ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares pour financer le développement de thérapies biotechnologiques. Details de l'offre, stabilisation et prévisions financières

Biotechnologie Abivax Ads Offre Publique Modalités Définitives
PRESS RELEASE

published on 07/24/2025 at 14:40, 10 months 29 days ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces the trading resumption of its ordinary shares on Euronext Paris after a temporary halt for a public offering confirmation and pricing announcement

Euronext Paris Abivax Public Offering Clinical-stage Biotechnology Trading Resumption
PRESS RELEASE

published on 07/24/2025 at 14:40, 10 months 29 days ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Négociations Traitements
PRESS RELEASE

published on 07/24/2025 at 14:40, 10 months 29 days ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax announces pricing of $650M (€554M) public offering of American Depositary Shares to fund clinical development and working capital, with expected closing on July 28, 2025

Abivax Clinical Development Public Offering Pricing Closing
PRESS RELEASE

published on 07/24/2025 at 14:40, 10 months 29 days ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités de son offre de 650M$ d'American Depositary Shares pour financer des développements cliniques. Stabilisation et options incluses

Abivax Développement Clinique Offre Publique Stabilisation American Depositary Shares
BRIEF

published on 07/24/2025 at 07:35, 10 months 29 days ago

Abivax suspend temporairement sa cotation sur Euronext Paris

Euronext Paris Biotechnologie Abivax Offre Publique Suspension Des Échanges

Published on 06/22/2026 at 19:45, 38 minutes ago

Trans Canada Gold Appoints Paradigm Drilling Ltd. for Drilling at the Harrison Lake District Scale Gold Project, Drilling to Commence Shortly
Published on 06/22/2026 at 15:58, 4 hours 25 minutes ago

Metallic Minerals Closes Upsized C$10.3 Million Bought Deal LIFE Private Placement
Published on 06/22/2026 at 15:30, 4 hours 53 minutes ago

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Published on 06/22/2026 at 15:00, 5 hours 23 minutes ago

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Published on 06/22/2026 at 14:01, 6 hours 22 minutes ago

Worksport (NASDAQ:WKSP) Achieves 35% May Gross Margin, Lands Meyer Distribution, Targets $36M+ Revenue Run-Rate

View all ACCESSWIRE

Published on 06/22/2026 at 19:27, 56 minutes ago

Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 06/22/2026 at 18:54, 1 hour 28 minutes ago

EQS-Adhoc: Brenntag SE publishes preliminary operating EBITDA for the second quarter of 2026 and increases its guidance for the financial year 2026
Published on 06/22/2026 at 18:30, 1 hour 52 minutes ago

Amprion welcomes RWE’s entry into M31
Published on 06/22/2026 at 18:30, 1 hour 53 minutes ago

Avolta awarded 10-year contract at Orlando International Airport across travel retail and F&B
Published on 06/22/2026 at 18:05, 2 hours 18 minutes ago

Bybit EU Strengthens European Positioning Ahead of MiCAR Transition

View all EQS

Published on 06/22/2026 at 18:45, 1 hour 38 minutes ago

Governance evolution
Published on 06/22/2026 at 18:45, 1 hour 38 minutes ago

ÉVOLUTION DE LA GOUVERNANCE
Published on 06/22/2026 at 18:16, 2 hours 6 minutes ago

ANTOINE FREY INCREASES HIS STAKE IN FREY
Published on 06/22/2026 at 18:16, 2 hours 6 minutes ago

ANTOINE FREY SE RENFORCE AU CAPITAL DE FREY
Published on 06/22/2026 at 18:00, 2 hours 23 minutes ago

GUILLEMOT CORPORATION : DECES DE M. CLAUDE GUILLEMOT, Président du Groupe GUILLEMOT CORPORATION

View all LES ECHOS COMFI WIRE

News